ReviewJournal of hepatocellular carcinoma2026
Discontinuing Immune Checkpoint Inhibitor-Based Therapy After Complete Response in Unresectable Hepatocellular Carcinoma: Evidence, Bias, and a Research Framework.
Yujia He et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.